Preclinical Trials Demonstrate the Efficacy of Nanoparticle-Based Vaccine Written by AZoNanoMay 25 2021 Preclinical studies have demonstrated the effectiveness of an experimental flu vaccine that contains scores of microscopic spherical sacs carrying infection-fighting proteins all through the body. The circle-shaped objects in the image above are cobalt-porphyrin-phospholipid (CoPoP) nanoparticles decorated with flu proteins. Image Credit: University at Buffalo. As explained in a study recently published in the Proceedings of the National Academy of Sciences on May 24 th, 2021, the experimental flu vaccine can: Enhance the effectiveness of seasonal flu vaccines, which generally work 40% to 60% of the time, as per the U.S. Centers for Disease Control and Prevention